KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Debt: 2016-2025

Historic Total Debt for Alnylam Pharmaceuticals (ALNY) over the last 3 years, with Sep 2025 value amounting to $121.3 million.

  • Alnylam Pharmaceuticals' Total Debt was N/A to $121.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.3 million, marking a year-over-year change of. This contributed to the annual value of $93.8 million for FY2024, which is N/A change from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Total Debt stood at $121.3 million, which was up 0.41% from $120.8 million recorded in Q2 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Total Debt peaked at $675.7 million during Q4 2021, and registered a low of $93.8 million during Q4 2024.
  • For the 2-year period, Alnylam Pharmaceuticals' Total Debt averaged around $113.5 million, with its median value being $119.5 million (2025).
  • Data for Alnylam Pharmaceuticals' Total Debt shows a peak YoY soared of 253.25% (in 2021) over the last 5 years.
  • Quarterly analysis of 3 years shows Alnylam Pharmaceuticals' Total Debt stood at $675.7 million in 2021, then followed by $93.8 million in 2024, then followed by $121.3 million in 2025.
  • Its Total Debt stands at $121.3 million for Q3 2025, versus $120.8 million for Q2 2025 and $118.1 million for Q1 2025.